Bright Light Exposure in Surgical Patients
Bright Light Exposure in Patients Undergoing Non-cardiac Elective Surgery
University of Colorado, Denver
70 participants
Jul 12, 2019
INTERVENTIONAL
Conditions
Summary
1. Elucidate the influence of intense light therapy pretreatment in patients undergoing cardiac surgery. We hypothesize that intense light exposure is associated with the peripheral stabilization of Per2 in human buccal swabs and plasma samples before surgery and with a decrease of Troponin I levels after surgery. In addition, we hypothesize that light therapy leads to Per2 dependent metabolic optimization in the human cardiac tissue. Therefore, a small piece of human heart tissue from the right atrium will be collected during cardiac cannulation, which will be otherwise discarded. 2. Critical illness (being in the intensive care unit) results in circadian malfunction and vessels not working. Vessel function is controlled by the body's circadian clock. Intense light boosts the circadian clock and the vessel function in animal studies. Vessels not working well in critical ill patients results in a myriad of severe diseases (delirium, stroke, heart attack, organ damage etc). Thus we will test if intense light can be used to boost the circadian clock and the associated vessel function in critical ill patients.
Eligibility
Inclusion Criteria3
- Patients undergoing primary sternotomy cardiac surgery
- Subjects in the range of 18 - 90 years old .
- Patient need to be in sinus rhythm at the time of surgery.
Exclusion Criteria10
- patients <18 or >90 years old
- participation in other clinical trials within the previous 30 days
- pregnancy
- neurological conditions that could impair weaning from ventilator support
- significant CNS disorders or comorbid irreversible conditions with a six-month mortality rate more than 50 percent
- prisoners, or subjects with altered capabilities to make decision will be enrolled
- medical history of type 2 diabetes
- patients with atrial fibrillation or use of class III anti-arhythmic drug
- patients with a left ventricle ejection fraction < 40%
- patient in emergency condition
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients are exposed to daylight for up to 10 days prior to surgery
Patients are exposed to placebo light for up to 10 days prior to surgery
ICU Patients are exposed to daylight for up to 10 days after surgery
ICU Patients are exposed to placebo light for up to 10 days after surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03822949